Greek Registry Of Essential Thrombocythemia: Baseline Characteristics and Therapeutic Strategy

• Published in: Blood 2013-11, Vol.122 (21), p.4084-4084
• Main Authors: Sotiropoulos, Damianos, Symeonidis, Argiris, Papadopoulos, Vassilios K, Tsirigotis, Panagiotis, Pagoni, Maria, Vassou, Amalia, Hatzimichael, Eleftheria, Spanoudakis, Emmanouil, Kotsianidis, Ioannis, Kouraklis, Alexandra, Lampropoulou, Polyxeni, Kotsopoulou, Maria, Megalakaki, Aikaterini, Matsouka, Charis, Barbarousi, Despina, Papadakis, Emmanouil S, Vourtsi, Aggeliki, Pouli, Anastasia, Sioni, Anastasia, Protopapa, Maria, Bitzioni, Aikaterini, Pidagitou, Anna, Dimou, Maria, Tsokanas, Dimitris, Bouchla, Anthoula, Apostolou, Chrysa, Vlachaki, Efthimia, Georgopoulos, Christos, Anagnostopoulos, Nikolaos, Briasoulis, Evangelos, Anagnostopoulos, Achilles, Panayiotidis, Panayiotis, Marinakis, Theodoros
• Format: Article
• Language: English
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.V122.21.4084.4084

The Greek Registry of Essential Thrombocythemia (ET) is implemented under the auspices of the Acute Leukemias and Myeloproliferative Neoplasms Study Group of the Hellenic Society of Haematology. Hereby, we present results after four years of retrospective data collection. The total number of patients included is 1078, from 14 Greek sites; ET was diagnosed between 1982 and 2012. The male to female ratio is 1:1.19. Median age at diagnosis is 63 years, median platelet counts (PLT) 826x109/L, hemoglobin (Hb) 13.6 g/dL, white blood cell counts (WBC) 9.4x109/L. The presenting symptoms were a thrombotic event in 6.8%, a hemorrhagic event in 1.5% of patients. In 79.8% of the patients the diagnosis was made after incidental finding of elevated platelet counts on routine laboratory investigation. Molecular studies were performed in 677 patients and 42.8% of them were positive for the JAK2-V617F mutation. The presence of JAK2-V617F mutation (mutant vs wild type allele) was associated with baseline platelet counts (757.5 vs 882 x109/L) and hemoglobin levels (14.4 vs 13.4 g/dL), p60 years, history of thrombosis and first line therapy. The history of thrombosis was the only statistically significant risk factor with odds ratio (OR) 3.9 (p=0.0005), while PLT was not a statistically significant risk factor (OR=2.5, p=0.074). Antiplatelet therapy was offered in 80% of patients (aspirin in 59.1%, clopidogrel in 4.7%, and combination therapy in 6.5%); anticoagulants (low molecular weight heparin or warfarin) were given in 2.3%, while the remaining 17.8% of patients did not receive any antithrombotic therapy. During the first six months post diagnosis, 31.6% of patients did not need any cytoreductive therapy. The rest 68.4% of the patients receiv